Apellis Pharmaceuticals (APLS) said Monday that Australia's Therapeutic Goods Administration approved Syfovre for the every-other-month treatment of geographic atrophy in adults with age-related macular degeneration resulting in vision loss.
The decision was supported by 24-month data from phase 3 studies, which showed that both monthly and every-other-month use of the treatment reduced GA progression and was generally well tolerated, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。